Tacrolimus with Mycophenolate Mofetil (MMF) or Sirolimus vs. Cyclosporine with MMF in Cardiac Transplant Patients: 1-Year Report
06/2006
Journal Article
Authors:
Kobashigawa, J.;
Miller, L.;
Russell, S.;
Ewald, G.;
Zucker, M.;
Goldberg, L.;
Eisen, H.;
Salm, K.;
Tolzman, D.;
Gao, J.;
Fitzsimmons, W.;
First, M.;
Investigators, S.
Secondary:
Am J Transplant
Volume:
6
Pagination:
1377-1386
URL:
http://www.ncbi.nlm.nih.gov/pubmed/16686761
Keywords:
Adult; Antiviral Agents; Combination; Cyclosporine; Cytomegalovirus Infections; Drug Therapy; Female; Graft Rejection; Heart Transplantation; Heart-Lung Transplantation; Hypolipidemic Agents; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid
Abstract:
{The most advantageous combination of immunosuppressive agents for cardiac transplant recipients has not yet been established. Between November 2001 and June 2003, 343 de novo cardiac transplant recipients were randomized to receive steroids and either tacrolimus (TAC) + sirolimus (SRL), TAC + mycophenolate mofetil (MMF) or cyclosporine (CYA) + MMF. Antilymphocyte induction therapy was allowed for up to 5 days. The primary endpoint of >/=3A rejection or hemodynamic compromise rejection requiring treatment showed no significant difference at 6 months (TAC/MMF 22.4%, TAC/SRL 24.3%, CYA/MMF 31.6%
